Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18674179 | Bead-based analysis of a sample | May 2024 | January 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18227151 | ELISA FOR DIAGNOSIS OF HAEMONCHUS LONGISTIPES INFECTION IN CAMELS | July 2023 | February 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18227030 | ELISA FOR DIAGNOSIS OF HAEMONCHUS LONGISTIPES INFECTION IN CAMELS | July 2023 | December 2023 | Allow | 5 | 2 | 0 | Yes | No |
| 18209814 | REAGENT COMPOSITION FOR DETECTION OF NON-HEMATOPOIETIC TUMOR AND USE THEREOF | June 2023 | July 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18204311 | COMPOSITIONS AND METHODS FOR PLASMAPHERESIS | May 2023 | March 2025 | Allow | 21 | 3 | 1 | Yes | No |
| 18200301 | Bead-based analysis of a sample | May 2023 | February 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18139242 | MAGNETIC REMOVAL OR IDENTIFICATION OF DAMAGED OR COMPROMISED CELLS OR CELLULAR STRUCTURES | April 2023 | February 2025 | Allow | 22 | 1 | 0 | No | No |
| 18124224 | METHOD FOR LABELING INTRACELLULAR AND EXTRACELLULAR TARGETS OF LEUKOCYTES | March 2023 | May 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18120887 | SYSTEM AND METHOD FOR SAMPLE PRESERVATION | March 2023 | August 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18114130 | METHOD AND SYSTEM FOR BUOYANT-PARTICLE-ASSISTED CELL THERAPY | February 2023 | November 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 18170852 | Methods for isolating target cells from blood | February 2023 | February 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18167557 | INDICATOR-BASED ANALYSIS OF A SAMPLE | February 2023 | June 2024 | Allow | 16 | 2 | 1 | Yes | No |
| 18164275 | IMMUNOASSAYS FOR HIGH POSITIVELY CHARGED PROTEINS | February 2023 | June 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 18105582 | COMPOSITIONS AND METHODS FOR PASSIVE OPTICAL BARCODING FOR MULTIPLEXED ASSAYS | February 2023 | March 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 17989895 | MONOCLONAL ANTIBODIES WITH SPECIFICITY FOR FETAL ERYTHROID CELLS | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17998361 | ASSAYS FOR THE DETECTION OF A BLOCKING ANALYTE | November 2022 | November 2024 | Abandon | 24 | 0 | 1 | No | No |
| 18052661 | FLOW CYTOMETRY EVALUATION OF BIOLOGICAL MATERIAL FOR UNASSOCIATED VIRUS-SIZE PARTICLES | November 2022 | November 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17959725 | ANTIBODY STAIN WITH LOW FLUOROPHORE RATIO FOR STAINING VIRUS-SIZE PARTICLES | October 2022 | August 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17945651 | BIOMARKER TEST AND METHOD FOR ASSESSING MUCOSAL HEALING IN RESPONSE TO TREATMENT OF ULCERATIVE COLITIS | September 2022 | March 2025 | Abandon | 30 | 2 | 0 | Yes | No |
| 17944439 | PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING | September 2022 | October 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17941212 | ELISA FOR DIAGNOSIS OF HAEMONCHUS LONGISTIPES INFECTION IN CAMELS | September 2022 | July 2023 | Allow | 10 | 1 | 1 | No | No |
| 17902095 | PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTING | September 2022 | December 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17902102 | METHODS OF ANALYSIS OF BLOOD FROM DECEASED DONORS | September 2022 | January 2025 | Abandon | 28 | 1 | 1 | No | No |
| 17898074 | SPECIMEN ENRICHMENT FOR OPTICAL TOMOGRAPHY CELL ANALYSIS | August 2022 | April 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 17818671 | ANTIBODIES FOR DETECTION AND ENRICHMENT OF FETAL CELLS AND THEIR USE | August 2022 | September 2024 | Allow | 25 | 1 | 1 | No | No |
| 17813899 | METHODS AND USES FOR REMOTELY TRIGGERED PROTEASE ACTIVITY MEASUREMENTS | July 2022 | June 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17758412 | METHODS OF ISOLATING A BIOLOGICAL ENTITY | July 2022 | December 2023 | Allow | 17 | 1 | 1 | No | No |
| 17856033 | KIT FOR DETECTING ANTI-PROTEASOME SUBUNIT ALPHA TYPE 1-IMMUNOGLOBULIN G (IgG) ANTIBODY | July 2022 | December 2023 | Abandon | 17 | 1 | 1 | No | No |
| 17803380 | Microbiology test card | June 2022 | January 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17828177 | ANALYSIS METHOD AND ANALYSIS DEVICE | May 2022 | October 2024 | Allow | 29 | 1 | 0 | No | No |
| 17826283 | KERATIN 17 AS A BIOMARKER FOR BLADDER CANCER | May 2022 | December 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17729528 | CHO HOST CELL PROTEIN ASSAY | April 2022 | September 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17721930 | HYBRID YEAST CELL LINES FOR HIGH LEVEL PRODUCTION OF RECOMBINANT PROTEIN | April 2022 | June 2025 | Allow | 38 | 1 | 1 | No | No |
| 17655401 | METHODS AND COMPOSITIONS FOR REMOVING BIOTIN INTERFERENCE FROM ASSAYS USING CONJUGATED MOLECULAR TRAPS | March 2022 | June 2024 | Allow | 27 | 1 | 0 | No | No |
| 17674967 | Bead-based analysis of a sample | February 2022 | May 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17650579 | COMPOSITIONS, KITS, AND METHODS FOR MULTIPLEX ASSAYS TO CORRECT FOR BIOTIN INTERFERENCE IN TARGET ANALYTE MEASUREMENTS | February 2022 | June 2024 | Allow | 28 | 1 | 0 | No | No |
| 17650443 | METHODS FOR SINGLE MOLECULE ANALYTE DETECTION | February 2022 | November 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17667153 | METHOD FOR THE FORMATION AND USE OF AN IMMUNOLABELING COMPLEX | February 2022 | May 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17589067 | CHO HOST CELL PROTEIN ASSAY | January 2022 | September 2024 | Allow | 31 | 1 | 0 | No | No |
| 17569551 | Method for Magnetically Labeling Particles and Labeling Apparatus | January 2022 | May 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17513080 | ISOLATION OF CELLS OF EPITHELIAL ORIGIN CIRCULATING IN PERIPHERAL BLOOD | October 2021 | April 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17501784 | METHOD FOR PREDICTING AND MONITORING CLINICAL RESPONSE TO IMMUNOMODULATORY THERAPY | October 2021 | April 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17491424 | METHODS FOR MEASURING UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 LEVELS IN BLOOD | September 2021 | June 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17469225 | TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHOD | September 2021 | March 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17466654 | DEVICES AND METHODS FOR MAGNETIC ISOLATION AND ANALYSIS OF RARE CELLS | September 2021 | April 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17388223 | METHOD FOR MEASURING IMMUNOSTIMULATORY RESPONSE OF IMMUNE CELL, METHOD FOR DETERMINING ABILITY TO FORM IMMUNE SYNAPSE IN IMMUNE CELL, AND CELL ANALYZER | July 2021 | June 2023 | Allow | 23 | 1 | 0 | No | No |
| 17366233 | ANALYTE DETECTION AND METHODS THEREFOR | July 2021 | December 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17349682 | UPCONVERSION FOR MICROSCOPY | June 2021 | April 2023 | Allow | 22 | 2 | 1 | Yes | No |
| 17349710 | INDICATOR-BASED ANALYSIS OF A SAMPLE | June 2021 | November 2022 | Allow | 17 | 2 | 1 | Yes | No |
| 17414788 | METHOD FOR SELECTING BIOLOGICAL BINDING MOLECULES | June 2021 | January 2023 | Allow | 19 | 1 | 0 | No | No |
| 17325681 | ASSAYS FOR THE DETECTION OF A BLOCKING ANALYTE | May 2021 | January 2023 | Allow | 20 | 3 | 2 | No | No |
| 17324685 | POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP | May 2021 | August 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17294183 | IMMUNOCHROMATOGRAPHIC TEST STRIP AND IMMUNOCHROMATOGRAPHIC DETECTION KIT | May 2021 | April 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17307127 | COMPOSITIONS AND METHODS FOR PASSIVE OPTICAL BARCODING FOR MULTIPLEXED ASSAYS | May 2021 | November 2022 | Allow | 19 | 1 | 1 | Yes | No |
| 17234182 | IDENTIFICATION OF PLATELET ACTIVATING ANTIBODIES | April 2021 | April 2025 | Allow | 48 | 1 | 2 | Yes | No |
| 17277912 | GLYCATED HEMOGLOBIN (%) ASSAY METHOD | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17276226 | METHOD OF DYNAMICS ANALYSIS FOR COMPOUND IN CELL | March 2021 | April 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17195416 | Methods, Reagents and Kits for Flow Cytometric Immunophenotyping | March 2021 | April 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17182859 | Activated GTPase-Based Assays and Kits for the Diagnosis of Sepsis and Other Infections | February 2021 | March 2025 | Allow | 48 | 1 | 2 | No | No |
| 17174917 | METHOD OF DETERMINING THE PRESENCE AND/OR AMOUNT OF TARGET MOLECULES | February 2021 | April 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17263800 | METHODS, KITS AND STAIN COMPOSITIONS FOR FLOW CYTOMETRY EVALUATION OF UNASSOCIATED VIRUS-SIZE PARTICLES USING MULTIPLE FLUOROGENIC DYES | January 2021 | September 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17148153 | SIMPLIFIED NUCLEI ANALYSIS PLATFORM AND BIOMARKER MATRIX THAT SUPPORTS GENOTOXIC MODE OF ACTION DETERMINATIONS | January 2021 | July 2023 | Allow | 30 | 1 | 0 | No | No |
| 17250347 | METHODS FOR DETECTION OF ABERRANT RESULTS CAUSED BY INCOMPLETE DISPERSION OF IMMUNOASSAY REAGENT | January 2021 | January 2025 | Allow | 48 | 2 | 0 | No | No |
| 17143463 | HDL-ASSOCIATED PROTEIN BIOMARKER PANEL DETECTION | January 2021 | March 2025 | Allow | 50 | 2 | 1 | No | No |
| 17139815 | Paired Microparticles-Based Kits for Detecting Analytes | December 2020 | August 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17132380 | ASSAY METHODS | December 2020 | August 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17130398 | FLOW CYTOMETRY FOR MONITORING HISTONE H3 METHYLATION STATUS | December 2020 | April 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17128877 | CAPTURE COMPOSITIONS | December 2020 | February 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17122054 | MEANS AND METHODS FOR THE DETERMINATION OF THE BIOLOGICAL ACTIVITY OF BONT/E IN CELLS | December 2020 | September 2023 | Allow | 33 | 1 | 0 | No | No |
| 17117455 | METHOD OF EVALUATING PROGRESSION OF AN INFECTIOUS DISEASE AND/OR INFLAMMATORY DISEASE | December 2020 | April 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17036042 | MULTIPLEX HIGH-THROUGHPUT FLOW CYTOMETRY DETECTION OF SARS-COV-2-SPECIFIC IgG, IgA AND IgM | September 2020 | June 2025 | Abandon | 57 | 2 | 1 | No | No |
| 17031732 | REAGENTS, METHODS AND KITS FOR DIAGNOSING PRIMARY IMMUNODEFICIENCIES | September 2020 | March 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 16995614 | Methods of Detecting Donor-Specific Antibodies and Systems for Practicing the Same | August 2020 | July 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 16990232 | Devices, Systems, and Methods for Cell Analysis in Microgravity | August 2020 | December 2024 | Abandon | 52 | 1 | 1 | No | No |
| 16987639 | METHOD FOR GENERATING HIGH AFFINITY ANTIBODIES | August 2020 | June 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 16945960 | BLOOD ANALYSIS SYSTEMS AND METHODS | August 2020 | August 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16941933 | MICRODEVICE FOR CELL SEPARATION UTILIZING ACTIVATION PHENOTYPE | July 2020 | February 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 16933658 | POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS | July 2020 | June 2024 | Allow | 47 | 4 | 1 | No | No |
| 16932453 | METHOD FOR DETERMINING ANALYTE-LIGAND BINDING ON A SENSOR SURFACE | July 2020 | June 2023 | Allow | 35 | 1 | 0 | No | No |
| 16921789 | COMPARTMENTALISED SCREENING BY MICROFLUIDIC CONTROL | July 2020 | April 2024 | Abandon | 46 | 1 | 1 | No | No |
| 16919173 | METHODS OF BH3 PROFILING | July 2020 | August 2023 | Allow | 38 | 2 | 0 | Yes | No |
| 16898250 | MULTIPLEXED TURBIDIMETRIC IMMUNOASSAYS TO MONITOR ENVIRONMENTAL CONTAMINATION | June 2020 | October 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16765255 | Drug Evaluation Method | May 2020 | November 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16877176 | IDENTIFICATION AND ISOLATION OF HUMAN CORNEAL ENDOTHELIAL CELLS (HCECS) | May 2020 | March 2023 | Allow | 34 | 2 | 0 | No | No |
| 16851651 | CYTOMETRIC BEAD ARRAY ANALYSIS | April 2020 | April 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16756415 | METHOD FOR MEASURING CELLULAR UPTAKE OF MOLECULES | April 2020 | October 2024 | Allow | 54 | 1 | 2 | Yes | No |
| 16840220 | MULTI-SPECTRAL MICROPARTICLE-FLUORESCENCE PHOTON CYTOMETRY | April 2020 | July 2023 | Allow | 40 | 2 | 1 | No | No |
| 16837900 | Multi-color Flow Cytometric Analysis of Samples with Low Cell Numbers | April 2020 | August 2024 | Allow | 52 | 4 | 0 | Yes | No |
| 16830973 | FORWARD SCATTERED LIGHT DETECTION SYSTEM, FLOW CYTOMETER AND METHOD FOR MEASURING CELL DIAMETER | March 2020 | October 2023 | Allow | 42 | 1 | 1 | No | No |
| 16647413 | FLOW BASED ASSAYS FOR THERAPEUTICS | March 2020 | February 2023 | Allow | 35 | 4 | 1 | Yes | No |
| 16796032 | Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens | February 2020 | February 2025 | Allow | 60 | 3 | 1 | No | No |
| 16792461 | COMPOSITIONS COMPRISING RESURFACED CELL-PENETRATING NANOBODIES AND METHODS OF USE THEREOF | February 2020 | December 2022 | Abandon | 34 | 0 | 1 | No | No |
| 16636715 | METHOD FOR MEASURING OCCUPANCY RATE OF SPECIFIC BINDING SUBSTANCES IN CELL POPULATION | February 2020 | August 2022 | Allow | 31 | 2 | 1 | No | No |
| 16781382 | Flow cytometry evaluation for virus-size particles with antibody stain having low fluorophore ratio | February 2020 | October 2022 | Allow | 33 | 1 | 1 | No | No |
| 16774920 | METHODS FOR THE MONITORING AND PROGNOSIS OF A CANCER | January 2020 | January 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16752155 | SYSTEMS, METHODS, AND BIOMARKERS FOR DETERMINING THE METABOLIC STATE OF RED BLOOD CELLS AND PLATELETS | January 2020 | August 2024 | Allow | 55 | 3 | 1 | Yes | No |
| 16714999 | METHODS AND KITS FOR IDENTIFYING EFFECTOR TREG CELLS | December 2019 | February 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16695976 | DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS | November 2019 | March 2023 | Allow | 40 | 1 | 1 | No | No |
| 16613723 | KITS, METHODS AND THEIR USES FOR DETECTING CELL-CELL INTERACTIONS IN A SAMPLE | November 2019 | February 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16611700 | COMPOSITIONS AND METHODS FOR LYSIS OF RED BLOOD CELLS | November 2019 | August 2022 | Allow | 33 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GABEL, GAILENE.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner GABEL, GAILENE works in Art Unit 1678 and has examined 513 patent applications in our dataset. With an allowance rate of 77.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner GABEL, GAILENE's allowance rate of 77.0% places them in the 36% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by GABEL, GAILENE receive 1.91 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GABEL, GAILENE is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +43.7% benefit to allowance rate for applications examined by GABEL, GAILENE. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 34.2% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 54.5% of cases where such amendments are filed. This entry rate is in the 76% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 95.8% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 87.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.7% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 11.3% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.